Publications by authors named "Peggy Manders"

Claim this Profile
F
From opt-out to opt-in consent for secondary use of medical data and residual biomaterial: An evaluation using the RE-AIM framework.
Jennifer E Lutomski, Peggy Manders

PLoS One· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expanding the boundaries of previously obtained informed consent in research: Views from participants in the Personalised Risk-based Mammascreening study.
Jennifer E Lutomski, Linda Rainey, Milou de Jong, Peggy Manders, Mireille J M Broeders

Health Expect· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Protocol of the Healthy Brain Study: An accessible resource for understanding the human brain and how it dynamically and individually operates in its bio-social context.

PLoS One· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protocol of the Healthy Brain Study: An accessible resource for understanding the human brain and how it dynamically and individually operates in its bio-social context.

PLoS One· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recommendations for a Dutch Sustainable Biobanking Environment.
Rogier van der Stijl, Peggy Manders, Elisabeth W H M Eijdems

Biopreserv Biobank· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patients to learn from: on the need for systematic integration of research and care in academic health care.
Martin Boeckhout, Philip Scheltens, Peggy Manders, Cees Smit, Annelien L Bredenoord

J Clin Transl Res· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Stepwise Procedure to Define a Data Collection Framework for a Clinical Biobank.
Peggy Manders, Tessa M A Peters, Ariaan E Siezen, Iris A L M van Rooij, Roger Snijder

Biopreserv Biobank· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
International biobanks: do or do not?
Paul N Span, Peggy Manders

Future Sci OA· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Accuracy of Hereditary Diffuse Gastric Cancer Testing Criteria and Outcomes in Patients With a Germline Mutation in CDH1.
Rachel S van der Post, Ingrid P Vogelaar, Peggy Manders, Lizet E van der Kolk, Annemieke Cats

Gastroenterology· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimal age to start preventive measures in women with BRCA1/2 mutations or high familial breast cancer risk.
Madeleine M A Tilanus-Linthorst, Hester F Lingsma, D Gareth Evans, Deborah Thompson, Reinoutje Kaas, Peggy Manders

Int J Cancer· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK).
Anouk Pijpe, Nadine Andrieu, Douglas F Easton, Ausrele Kesminiene, Elisabeth Cardis, Peggy Manders

BMJ· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation study suggested no differential misclassification of self-reported mammography history in BRCA1/2 mutation carriers.
Anouk Pijpe, Renée L Mulder, Peggy Manders, , Flora E van Leeuwen

J Clin Epidemiol· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Body weight and risk of breast cancer in BRCA1/2 mutation carriers.
Peggy Manders, Anouk Pijpe, Maartje J Hooning, Irma Kluijt, Hans F A Vasen

Breast Cancer Res Treat· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physical activity and the risk of breast cancer in BRCA1/2 mutation carriers.
Anouk Pijpe, Peggy Manders, Richard M Brohet, J Margriet Collée, Senno Verhoef

Breast Cancer Res Treat· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reliability of self-reported diagnostic radiation history in BRCA1/2 mutation carriers.
Anouk Pijpe, Peggy Manders, Renée L Mulder, Flora E van Leeuwen, Matti A Rookus

Eur J Epidemiol· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Antonis C Antoniou, Amanda B Spurdle, Olga M Sinilnikova, Sue Healey, Karen A Pooley, Peggy Manders

Am J Hum Genet· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High survivin predicts a poor response to endocrine therapy, but a good response to chemotherapy in advanced breast cancer.
Paul N Span, Vivianne C G Tjan-Heijnen, Peggy Manders, Doorlene van Tienoven, Jeffrey Lehr

Breast Cancer Res Treat· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survivin is an independent prognostic marker for risk stratification of breast cancer patients.
Paul N Span, Fred C G J Sweep, Erwin T G Wiegerinck, Vivianne C G Tjan-Heijnen, Peggy Manders

Clin Chem· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
Peggy Manders, Vivianne C G Tjan-Heijnen, Paul N Span, Nicolai Grebenchtchikov, Anneke Geurts-Moespot

Cancer· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tissue inhibitors of metalloproteinase expression in human breast cancer: TIMP-3 is associated with adjuvant endocrine therapy success.
Paul N Span, Raija L P Lindberg, Peggy Manders, Vivianne C G Tjan-Heijnen, Joop J T M Heuvel

J Pathol· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The complex between urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-I) independently predicts response to first-line endocrine therapy in advanced breast cancer.
Peggy Manders, Vivianne C G Tjan-Heijnen, Paul N Span, Nicolai Grebenchtchikov, Anneke J Geurts-Moespot

Thromb Haemost· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mammaglobin is associated with low-grade, steroid receptor-positive breast tumors from postmenopausal patients, and has independent prognostic value for relapse-free survival time.
Paul N Span, Esmé Waanders, Peggy Manders, Joop J T M Heuvel, John A Foekens

J Clin Oncol· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive impact of urokinase-type plasminogen activator: plasminogen activator inhibitor type-1 complex on the efficacy of adjuvant systemic therapy in primary breast cancer.
Peggy Manders, Vivianne C G Tjan-Heijnen, Paul N Span, Nicolai Grebenchtchikov, John A Foekens

Cancer Res· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vascular endothelial growth factor independently predicts the efficacy of postoperative radiotherapy in node-negative breast cancer patients.
Peggy Manders, Fred C G J Sweep, Vivianne C G Tjan-Heijnen, Anneke Geurts-Moespot, Doorléne T H van Tienoven

Clin Cancer Res· December 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vascular endothelial growth factor is associated with the efficacy of endocrine therapy in patients with advanced breast carcinoma.
Peggy Manders, Louk V A M Beex, Vivianne C G Tjan-Heijnen, Paul N Span, C G J Sweep

Cancer· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis